MedTrace Logo

Study of Phenobarbital Inhibition of Catamenial Epilepsy

NCT00530413 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-12-10

No results posted yet for this study

Summary

The purpose of this study is to test the effectiveness of low-dose Phenobarbital on the treatment of catamenial epilepsy.

We propose that since the catamenial seizures are associated with the reduction in levels of GABA-enhancing allopregnanolone, short-term replacement with the GABAR-enhancing agent Phenobarbital will reduce the incidence of catamenial seizures.

Conditions

Interventions

DRUG

Phenobarbital

Phenobarbital will be given based on weight range

OTHER

Placebo

Placebo group

Sponsors & Collaborators

  • University of Toledo Health Science Campus

    lead OTHER

Principal Investigators

  • Lazar J Greenfield, Jr, MD, PhD · University of Toledo Health Science Campus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00530413 on ClinicalTrials.gov